April 11 (Reuters) - Moderna Inc said on Tuesday it expects sales from its respiratory vaccines to be between $8 billion and $15 billion in 2027.
The company said ahead of its annual vaccines conference on Tuesday that it expects to launch six major vaccines in the next few years.
Moderna is testing vaccines against respiratory syncytial virus (RSV), influenza and a next-generation COVID-19 shot in late-stage studies. (Reporting by Bhanvi Satija and Aditya Samal in Bengaluru; Editing by Shinjini Ganguli)
